STENOCARE A/S is ready with new medical cannabis product

STENOCARE has been working with The Danish Medicines Agency to have a new CBD medical cannabis capsule product approved for market release. The Danish Medicines Agency has now chosen to approve the product for listing on the Medicine List, which will make STENOCARE the first company in the Danish Medical Cannabis Program to introduce capsules for Danish patients. The new product is named “CBD Capsules STENOCARE” and contain medical cannabis oil in vegan capsules. It is expected that the product will be available at Danish pharmacies late-Summer 2019.

STENOCARE was the first in the Program to introduce medical cannabis oil products for Danish patients. The company has been monitoring the use of their three oil products since September 2018 and got the feedback from doctors and patients that they would also value having access to capsule-based products. Therefore, STENOCARE announced in December 2018 the plan to have three new medical cannabis capsule products accepted for the Danish Medicine List. Today, the Danish Medicine Agency and STENOCARE completed their work with the first product. The remaining two capsule products, THC Capsules STENOCARE and 1:1 Capsules STENOCARE are pending the acceptance for the Danish Medicines List.

The new CBD Capsules STENOCARE product contain 10 mg CBD and less than 1 mg THC in a vegan capsule. The product contains 60 capsules that patients can dose orally.

Thomas Skovlund Schnegelsberg, CEO STENOCARE comments:

“We are proud to once again be able to respond to needs from doctors and patients. They have told us they would like more choice with medical cannabis, and convenient dosage with capsules is a high priority. The capsules are vegan based – as this will therefore also be available for patients that cannot use the more widely used gelatin-based capsules.”

The CBD Capsules STENOCARE product is produced and supplied by STENOCARE’s strategic partner CannTrust Inc, a leading Canadian producer of medical cannabis. With the announcement today, CannTrust and STENOCARE are first-movers with creating a new capsule category of products based on the cannabis plant. The new category is expected to partly help existing patients and attract new patients that previously found it difficult to dose the oil products with an oral syringe. It is expected that CBD Capsules STENOCARE will be available at Danish pharmacies late-Summer 2019.

For additional information regarding, please contact:
Thomas Skovlund Schnegelsberg, CEO
P
hone: +45 31770060
E-mail: presse@stenocare.com

About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot program. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers medical cannabis oil that comply with the strict Danish regulatory requirements. STENOCARE is also developing a separate production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.

About Us

STENOCARE A/S is founded in 2017 to work with the Danish legalization program for medical cannabis to give better quality of life for patients. The company import’s and sell finished products for the Danish market via distributors. STENOCARE has approvals from the Danish Medicine Agency to supply pharmacies and hospitals with medical cannabis oil products. The company will build a production facility to cultivate and manufacture their own finished medical cannabis products for patients in Denmark and Europe, and thereby command the entire value chain and secure supply capacity. STENOCARE has a strategic partner, CannTrust Inc, that is providing their technology and knowhow for production of medical cannabis.

Subscribe

Documents & Links